Sugi Predict

Sugi Predict / Targets / BCL3

BCL3

B-cell lymphoma 3 protein · P20749 · BCL3 on Sugi Atlas →

1,998 patent compounds predicted against BCL3, 1,243 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8223960 SCHEMBL8223960 0.70 7/20
SCHEMBL8161181 SCHEMBL8161181 0.84 6/20
SCHEMBL12181337 SCHEMBL12181337 0.66 6/20
SCHEMBL2412603 SCHEMBL2412603 0.61 6/20
SCHEMBL4200900 SCHEMBL4200900 0.61 6/20
SCHEMBL5258790 SCHEMBL5258790 0.59 6/20
SCHEMBL1292531 SCHEMBL1292531 0.59 6/20
SCHEMBL4600379 SCHEMBL4600379 0.56 6/20
SCHEMBL11465420 SCHEMBL11465420 0.53 6/20
SCHEMBL9229341 SCHEMBL9229341 0.71 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL10767844) 0.62 5/20
SCHEMBL1292338 SCHEMBL1292338 0.60 5/20
SCHEMBL5238111 SCHEMBL5238111 0.56 5/20
SCHEMBL4548139 SCHEMBL4548139 0.56 5/20
SCHEMBL6015635 SCHEMBL6015635 0.56 5/20
SCHEMBL10819821 SCHEMBL10819821 0.54 5/20
SCHEMBL2025063 SCHEMBL2025063 0.53 5/20
SCHEMBL8169156 SCHEMBL8169156 0.53 5/20
SCHEMBL8221954 SCHEMBL8221954 0.52 5/20
SCHEMBL10132765 SCHEMBL10132765 0.52 5/20

Clinical trials — most relevant to BCL3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Lithium As a Treatment to Prevent Impairment of Cognition in Elders PHASE4COMPLETED
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia PHASE3COMPLETED
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE3COMPLETED
Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients PHASE3UNKNOWN
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations PHASE2ACTIVE_NOT_RECRUITING
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma PHASE1/PHASE2RECRUITING
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma PHASE2RECRUITING
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL PHASE1/PHASE2RECRUITING
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma PHASE2COMPLETED
Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma PHASE2COMPLETED
DALY II Japan/MB-CART2019.1 for DLBCL PHASE2RECRUITING
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission PHASE2ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression PHASE2UNKNOWN
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia PHASE2COMPLETED
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL PHASE2COMPLETED
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme PHASE2COMPLETED
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases PHASE1COMPLETED
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA PHASE1RECRUITING
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma PHASE1ACTIVE_NOT_RECRUITING
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma PHASE1COMPLETED
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma PHASE1UNKNOWN
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme PHASE1COMPLETED
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients PHASE1COMPLETED
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma nanRECRUITING
A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular Lymphoma nanACTIVE_NOT_RECRUITING
Dietary Intervention With High Phenolic EVOO in CLL nanCOMPLETED
Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell Lymphomas nanNOT_YET_RECRUITING
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a BCL3 binder may also engage these)

ProteinNameSimilarity
Q9Z2F6 — 0.986 Q9Z2F6 →
Q8N6N2 — 0.959 Q8N6N2 →
O77638 — 0.958 O77638 →
O09112 — 0.957 O09112 →
Q3UR85 — 0.956 Q3UR85 →
O35779 — 0.956 O35779 →
PKN1 Serine/threonine-protein kinase N1 0.955 landscape →
Q9D6E4 — 0.954 Q9D6E4 →
Q66T02 — 0.953 Q66T02 →
Q99PV5 — 0.953 Q99PV5 →
Q9JJA9 — 0.952 Q9JJA9 →
A1A4I4 — 0.951 A1A4I4 →
Q6NS60 — 0.950 Q6NS60 →
A6QM06 — 0.950 A6QM06 →
Q9WTR8 — 0.950 Q9WTR8 →
Q0GA42 — 0.950 Q0GA42 →
A4D2P6 — 0.950 A4D2P6 →
Q9NRU3 — 0.950 Q9NRU3 →
NFATC1 Nuclear factor of activated T-cells, cytoplasmic 1 0.950 landscape →
Q8TF61 — 0.949 Q8TF61 →
Q9Z1B8 — 0.949 Q9Z1B8 →
Q13202 — 0.949 Q13202 →
Q7Z6J2 — 0.949 Q7Z6J2 →
Q96K62 — 0.949 Q96K62 →
O43189 — 0.949 O43189 →
Q99742 — 0.949 Q99742 →
Q96JH8 — 0.948 Q96JH8 →
P70268 — 0.948 P70268 →
Q96C00 — 0.948 Q96C00 →
Q9Y2G1 — 0.948 Q9Y2G1 →